Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the agreement, BWXT Medical, will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology, enabling Fusion for advancing its pipeline of targeted alpha therapies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2023
Lead Product(s) : Actinium-225
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : [225Ac]-FPI-1434
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : [111In]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide.
Brand Name : [225Ac]-FPI-1434
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : [225Ac]-FPI-1434
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Agreement
BWXT Medical Executes Commercial Agreement with Bayer for Supply of Actinium-225 Based Products
Details : Under the terms of the commercial agreement, Bayer will purchase high-purity Ac-225 from BWXT Medical at pre-determined prices. Ac-225 is a highly powerful radioisotope used in targeted alpha therapies (TATs).
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 27, 2022
Lead Product(s) : n.c.a Ac-225
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : TRIUMF
Deal Size : Undisclosed
Deal Type : Agreement
TRIUMF and BWXT Medical Execute Agreement for Manufacture of Ac-225 Based Products
Details : TRIUMF will irradiate thorium-232 targets for BWXT Medical. From this irradiated thorium, BWXT Medical will process and produce high purity n.c.a Ac-225, sometimes referred to as non-carrier-added Ac-225, for commercial sale, strengthening BWXT Medicalâ€...
Brand Name : n.c.a Ac-225
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2022
Lead Product(s) : n.c.a Ac-225
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : TRIUMF
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
